Klingel Karin, Sauter Martina, Bock C Thomas, Szalay Gudrun, Schnorr Jens-Jörg, Kandolf Reinhard
Department of Molecular Pathology, University Hospital of Tübingen, Liebermeisterstr. 8, 72076, Tuebingen, Germany.
Med Microbiol Immunol. 2004 May;193(2-3):101-7. doi: 10.1007/s00430-003-0190-1. Epub 2003 Aug 14.
Endomyocardial biopsy (EMB) is often performed in patients presenting with sudden onset of heart failure to identify myocarditis. The introduction of immunohistochemical techniques for the detection and differentiation of infiltrating immune cells, specific adhesion molecules and MHC class I and II molecules increased the prognostic value of EMB in the diagnosis of myocarditis considerably. A major breakthrough in the understanding of pathogenetic mechanisms in myocarditis was achieved by diagnostic use of molecular biological methods. By application of in situ hybridization and PCR, enteroviruses, and more recently, parvovirus B19 (PVB19) have been identified as relevant agents of myocarditis. The different cell tropism of these viruses implicates distinct pathogenic principles, which, at present, are not completely understood. Whereas enteroviruses damage the heart primarily via direct lysis of infected myocytes, PVB19 does not infect myocytes, but endothelial cells of small intracardiac arterioles and venules, resulting in impairment of myocardial microcirculation with secondary myocyte necrosis during acute infection. Histological and immunohistological stainings combined with molecular biological approaches in EMB will help us to resolve the question of whether patients with myocarditis should be treated by specific antiviral agents or by immunosuppressive therapies.
心内膜心肌活检(EMB)常用于突发心力衰竭的患者,以诊断是否患有心肌炎。免疫组织化学技术用于检测和区分浸润性免疫细胞、特定黏附分子以及MHCⅠ类和Ⅱ类分子,这大大提高了EMB在心肌炎诊断中的预后价值。分子生物学方法的诊断性应用在心肌炎发病机制的理解上取得了重大突破。通过原位杂交和聚合酶链反应(PCR),肠道病毒以及最近发现的细小病毒B19(PVB19)已被确定为心肌炎的相关病原体。这些病毒不同的细胞嗜性暗示了不同的致病原理,目前尚未完全明确。肠道病毒主要通过直接裂解受感染的心肌细胞来损害心脏,而PVB19并不感染心肌细胞,而是感染心内小动脉和小静脉的内皮细胞,导致急性感染期间心肌微循环受损,继而出现心肌细胞坏死。心内膜心肌活检中组织学和免疫组织学染色结合分子生物学方法,将有助于我们解决心肌炎患者应采用特异性抗病毒药物还是免疫抑制疗法进行治疗的问题。